In response to the SARS-CoV-2 pandemic, an unprecedented mobilization of the scientific community took place, focused on understanding various properties of the SARS-CoV-2 virus and developing drugs to treat and prevent COVID-19.
In line with the current, structure-based paradigm of drug discovery, structural biology has been among the leading disciplines supporting these efforts. Indeed, since the first structure of a SARS-CoV-2 protein was released at the beginning of February 2020, there has been a flood of three-dimensional models of SARS-CoV-2-related macromolecular targets, mostly determined by X-ray crystallography and cryo-electron microscopy (cryo-EM).